Mini-Oral Session

[MO43] Mini-Oral Session 43　Gastrointestinal Cancer 5（Miscellaneous）
【E】

Sat. Feb 19, 2022 3:50 PM - 4:40 PM Room 12 (Prince Hall 2, B2F, The Prince Kyoto Takaragaike)

Chair：Yasushi Tsuji（Department of Medical Oncology, Tonan Hospital），Ichinosuke Hyodo（Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center）

+Add all to schedule

[MO43-1] Aspirin and Nonsteroidal Anti-Inflammatory Drug (NSAIDs) and Associated Risk of Barrett's Esophagus: A Systematic Review

^○Billy Susanto¹, Sharon Chen¹, Andree Kurniawan² (1.Faculty of Medicine, Pelita Harapan University, 2.Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University)

[MO43-2] Effect of concomitant use of proton pump inhibitors (PPIs) on the efficacy of anti-PD-1 therapy for esophageal cancer

^○Ryuichi Morita¹, Takeshi Ishikawa^1,2, Kohei Asaeda¹, Reo Kobayashi¹, Hajime Miyazaki¹, Tomoki Sakakida¹, Toshifumi Doi¹, Ken Inoue¹, Osamu Dohi¹, Akito Harusato¹, Naohisa Yoshida¹, Kazuhiko Uchiyama¹, Tomohisa Takagi¹, Hirotaka Konishi³, Atsushi Shiozaki³, Hitoshi Fujiwara³, Hideyuki Konishi¹, Yoshito Itoh¹ (1.Department of Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 2.Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, 3.Divisions of Digestive Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine)

[MO43-3] Prognostic value of systemic inflammation score in patients treated with chemoradiotherapy for esophageal carcinoma

^○Kozue Kanemitsu, Yasunori Yamamoto, Masashi Hirooka, Eiji Takeshita, Yoshiou Ikeda, Bunzo Matsuura, Yoichi Hiasa (Department of Gastroenterology and Metabology, Ehime University)

[MO43-4] The impact of nutrition support and Glasgow prognostic score in advanced gastric cancer patients treated by chemotherapy

^○Keiji Sugiyama¹, Kazuhiro Shiraishi¹, Takuya Motohashi², Shinpei Onoda², Riko Nishibori¹, Mariko Sato¹, Kyoko Kato¹, Hiroaki Uda³, Masaya Suenaga³, Masaaki Shimada⁴, Noboru Hirashima⁴, Masato Kataoka³, Chiyoe Kitagawa¹ (1.Department of Medical Oncology, Nagoya Medical Center, 2.Department of Nutrition Service, Nagoya Medical Center, 3.Department of Surgery, Nagoya Medical Center, 4.Department of Gastroenterology, Nagoya Medical Center)

[MO43-5] Cost analysis of multiple drug chemotherapy for advanced gastric cancer

^○Keita Fukuyama¹, Yukiko Mori³, Taiki Taniguchi², Nomura Motoo³, Shigemi Matsumoto¹, Manabu Muto³ (1.Department of Real World Data Research and Development, Graduate School of Medicine, Kyoto University, 2.Ministry of Health, Labour and Welfare, Health Policy Bureau, Regional Medical Care Planning Division, 3.Department of Clinical Oncology, Kyoto University Hospital)

[MO43-6] Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers

^○Thierry Andre¹, Dominique Berton², Giuseppe Curigliano³, Susan L Ellard⁴, Jose Manuel Trigo Perez⁵, Hendrik-Tobias Arkenau⁶, Cyril Abdeddaim⁷, Wei Guo⁸, Ellie Im⁹, Naureen Starling¹⁰ (1.Sorbonne University and Saint-Antoine Hospital, 2.GINECO & Institut de Cancerologie de l'Ouest, Centre René Gauducheau, 3.Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, and University of Milano, 4.BC Cancer-Kelowna, 5.Medical Oncology Department, Hospital Ramón y Cajal, 6.Sarah Cannon Research Institute UK Limited, 7.Centre de Lutte Contre le Cancer-Centre Oscar Lambret, 8.START Madrid-FJD, Fundación Jiménez Diaz Hospital, 9.GlaxoSmithKline (GSK), 10.Royal Marsden Hospital NHS Foundation Trust)